Company News: Page (1) of 1 - 01/15/13 Email this story to a friend. email article Print this page (Article printing at page facebook


(January 15, 2013)

Category: Investment, Biotech, Pharma


Visit this company: Sunshine Biopharma Inc.

Montreal, Quebec, Canada - January 15, 2013 ( Newswire) Advanomics Corporation, the parent company of Sunshine Biopharma Inc. (OTCBB: SBFM), is pleased to announce that it has just filed in the United States a new patent application covering various manufacturing methodology and molecular aspects of Adva-27a. Advanomics intends to expand this new Adva-27a protection worldwide by filing appropriate international patent applications within the prescribed time limits from this initial filing. Advanomics has recently completed acquisition of the original Adva-27a worldwide patents filed in April 2007 from Institut National des Sciences Appliquees, a government research lab in France. If granted, this new patent filing will extend Adva-27a exclusivity by nearly six years, from April 2027 to January 2033.

Adva-27a is Sunshine Biopharma's lead anticancer compound, a small molecule that has recently been shown to be effective at killing multidrug resistant breast cancer cells as well as other aggressive cancer cells in vitro (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). Adva-27a is currently in the IND-Enabling stage of development. The original US patent covering Adva-27a was issued on August 7, 2012 under US patent number 8,236,935.

"Having an upgraded patent position is extremely important in the drug business", said Dr. Steve N. Slilaty, Sunshine Biopharma's CEO. "Coverage of the new molecular aspects of Adva-27a and the approximately six additional years of protection factor significantly into the Company's financial equations", he added.

About Sunshine Biopharma Inc. (OTCBB:SBFM)

Sunshine Biopharma is an early stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. Sunshine Biopharma recently announced that it has initiated IND-Enabling studies for its lead antitumor compound, Adva-27a.

About Advanomics Corporation

Advanomics Corporation is a privately held Canadian company focused on the research and development of treatments for cancer and other human diseases. Advanomics is conducting research and development in the area of Carbon-Difluoride Chemistry to generate novel anticancer compounds and in the area of RNA Technology for deciphering genomic information and rapid identification of disease related molecular targets for therapeutic intervention.

Safe Harbor Forward-Looking Statements

To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

For Additional Information Contact:

Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464

Published at newswire

About is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more .

Sign up for the free investor news and stock alerts at including biotech stocks:

Research more biotech stocks at biotech stock directory of TSX, OTC, NASDAQ and NYSE stocks :

Disclaimer/ Disclosure : The is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: SBFM is an expired news publication and content client on . was previously compensated and is long SBFM shares. More info : Investorideas was not compensated for this release.BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info:

Page: 1

Related Keywords:Manufacturing, Sales, Applications, Manufacturing/Production, Advertising, Manufacturing, Internet, Internet Server Applications, Business, Canada, France, USA, Inc., Medicine, Disease, Cancer, Surgery, Medication, Womens Health, Science, Financial, Lifestyle, Environmental Technology, Green Technology, Medical, Biology, Chemistry, Cancer, Business, Other,

laser printer
LaserJet Pro P1606DN Laser Printer (26 PPM, 600x600 DPI, B&W, 32MB, PC/Mac)
By HP (Hewlett-Packard), start from $ 209.99
With 111 Reviews.
LaserJet Pro P1102w Laser Printer (19 PPM, 600x600 DPI, B&W, 8 MB, Wi-Fi, PC/Mac)
By HP (Hewlett-Packard), start from $ 99.99
With 234 Reviews.
LaserJet Pro 400 M451NW Laser Printer (20 ppm Mono / 20 ppm Color, 600x600 DPI, Color, 128 MB, Wi-Fi, PC/Mac)
By HP (Hewlett-Packard), start from $ 299.99
With 32 Reviews.
LaserJet Pro 400 M451DN Laser Printer (21 PPM, 600x600 DPI, Color, 128 MB, PC/Mac)
By HP (Hewlett-Packard), start from $ 328.98
With 17 Reviews.
LaserJet Pro 400 M475dw All-in-One Laser Printer (21 PPM, 600x600 DPI, Color, 192 MB, Wi-Fi, PC/Mac)
By HP (Hewlett-Packard), start from $ 749.99
With 25 Reviews.
LaserJet Pro 200 M251NW Laser Printer (14 PPM, 600x600 DPI, Color, Wi-Fi, PC)
By HP (Hewlett-Packard), start from $ 169.99
With 20 Reviews.
Content-type: text/html  Rss  Add to Google Reader or
Homepage    Add to My AOL  Add to Excite MIX  Subscribe in
NewsGator Online 
Real-Time - what users are saying - Right Now!

@ Copyright, 2014 Digital Media Online, All Rights Reserved